274 related articles for article (PubMed ID: 37119510)
1. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome.
Stone JK; Mehta NA; Singh H; El-Matary W; Bernstein CN
Fam Cancer; 2023 Oct; 22(4):413-422. PubMed ID: 37119510
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
4. Management of familial adenomatous polyposis and MUTYH-associated polyposis; new insights.
Aelvoet AS; Buttitta F; Ricciardiello L; Dekker E
Best Pract Res Clin Gastroenterol; 2022; 58-59():101793. PubMed ID: 35988966
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention in familial adenomatous polyposis.
Kim B; Giardiello FM
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):607-22. PubMed ID: 22122775
[TBL] [Abstract][Full Text] [Related]
6. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
[TBL] [Abstract][Full Text] [Related]
7. Familial adenomatous polyposis.
Half E; Bercovich D; Rozen P
Orphanet J Rare Dis; 2009 Oct; 4():22. PubMed ID: 19822006
[TBL] [Abstract][Full Text] [Related]
8. Hereditary colorectal cancer syndromes.
Strate LL; Syngal S
Cancer Causes Control; 2005 Apr; 16(3):201-13. PubMed ID: 15947872
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention Considerations in Patients with Hereditary Colorectal Cancer Syndromes.
Macaron C; Mankaney GN; Haider M; Mouchli M; Hurley K; Burke CA
Gastrointest Endosc Clin N Am; 2022 Jan; 32(1):131-146. PubMed ID: 34798982
[TBL] [Abstract][Full Text] [Related]
10. Prevention of colorectal cancer in high-risk populations: the increasing role for endoscopy and chemoprevention in FAP and HNPCC.
Lynch PM
Digestion; 2007; 76(1):68-76. PubMed ID: 17947820
[TBL] [Abstract][Full Text] [Related]
11. Endoscopic Surveillance and Treatment of Upper GI Tract Lesions in Patients with Familial Adenomatous Polyposis-A New Perspective on an Old Disease.
Paszkowski J; Samborski P; Kucharski M; Cwaliński J; Banasiewicz T; Pławski A
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553595
[TBL] [Abstract][Full Text] [Related]
12. Familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal cancer (HNPCC): a review of clinical, genetic and therapeutic aspects.
Soravia C; Bapat B; Cohen Z
Schweiz Med Wochenschr; 1997 Apr; 127(16):682-90. PubMed ID: 9140167
[TBL] [Abstract][Full Text] [Related]
13. Chemoprevention in familial adenomatous polyposis: past, present and future.
Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention in hereditary colorectal cancer syndromes.
Hawk E; Lubet R; Limburg P
Cancer; 1999 Dec; 86(11 Suppl):2551-63. PubMed ID: 10630181
[TBL] [Abstract][Full Text] [Related]
15. Familial adenomatous polyposis in pediatrics: natural history, emerging surveillance and management protocols, chemopreventive strategies, and areas of ongoing debate.
Septer S; Lawson CE; Anant S; Attard T
Fam Cancer; 2016 Jul; 15(3):477-85. PubMed ID: 27056662
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
17. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
Burn J; Mathers J; Bishop DT
Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
[TBL] [Abstract][Full Text] [Related]
18. Cohorts with familial disposition for colon cancers in chemoprevention trials.
Burt RW
J Cell Biochem Suppl; 1996; 25():131-5. PubMed ID: 9027609
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.
Thun MJ; Henley SJ; Patrono C
J Natl Cancer Inst; 2002 Feb; 94(4):252-66. PubMed ID: 11854387
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
